Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:34 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22015

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma
Interventions: Zanzalintinib, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 110 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX; Drug · Combination Product
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Fracture; Pelvic, Insufficiency Fractures, Fragility Fracture, Sacroiliac; Fusion, Sacroiliac Joint Disruption, Sacroiliac Joint Dysfunction
Interventions: iFuse TORQ TNT Implant System; Device
Lead sponsor: SI-BONE, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Edina, Minnesota • Rochester, Minnesota • Wyomissing, Pennsylvania

Conditions: Atopy, Primary Immunodeficiency, Autoimmunity, Autoinflammation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2042
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Severe Tricuspid Valve Regurgitation, Tricuspid Valve Regurgitation, Tricuspid Valve Disease, Cardiovascular Diseases (CVD), Heart Valve Diseases, Tricuspid Valve Insufficiency, Severe Heart Valve Disease, Symptomatic Tricuspid Regurgitation
Interventions: Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System, Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System; Device
Lead sponsor: Laplace Interventional, Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 2
States / cities: Tulsa, Oklahoma • Kingsport, Tennessee

Conditions: Lumbosacral Radiculopathy
Interventions: VER-01, Placebo; Drug · Other
Lead sponsor: Vertanical GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 32
States / cities: Mobile, Alabama • Tempe, Arizona • Long Beach, California + 28 more

Conditions: Bone Marrow Transplant (BMT)
Interventions: Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors); Other
Lead sponsor: Ossium Health, Inc.; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Birmingham, Alabama • Duarte, California • Detroit, Michigan + 2 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 495
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Interventions: SAR445877, FOLFOX6, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer's Disease
Interventions: Psilocybin, Cognitive Training; Drug · Other
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Recruiting clinical trials

Filter and sort this status page

Live official records

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures

NIAID Centralized Sequencing Protocol

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

HPC Offered for PRESERVE Expansion

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin